How does the metabolism of tumour cells differ from that of normal cells
暂无分享,去创建一个
F. Rumjanek | A. Galina | M. F. Rodrigues | N. Amoedo | Antonio Galina | Nívea Dias Amoêdo | Juan Perez Valencia | Mariana Figueiredo Rodrigues | Franklin David Rumjanek | Juan P. Valencia
[1] R. Deberardinis,et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.
[2] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[3] A. Goffeau,et al. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae , 2012, Journal of Bioenergetics and Biomembranes.
[4] Jesse M. Platt,et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability , 2011, Proceedings of the National Academy of Sciences.
[5] B. Van Houten,et al. Metabolic symbiosis in cancer: Refocusing the Warburg lens , 2013, Molecular carcinogenesis.
[6] G. Semenza. HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.
[7] R. Rossignol,et al. Mitoplasticity: adaptation biology of the mitochondrion to the cellular redox state in physiology and carcinogenesis. , 2013, Antioxidants & redox signaling.
[8] Saroj P. Mathupala,et al. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.
[9] A. Cassago,et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism , 2012, Proceedings of the National Academy of Sciences.
[10] A. Goffeau,et al. Yeast ATP-binding cassette transporters conferring multidrug resistance. , 2012, Annual review of microbiology.
[11] D. Tang,et al. PKM2, a Central Point of Regulation in Cancer Metabolism , 2013, International journal of cell biology.
[12] P. Vaupel,et al. Availability, not respiratory capacity governs oxygen consumption of solid tumors. , 2012, The international journal of biochemistry & cell biology.
[13] A. Galina,et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. , 2009, The Biochemical journal.
[14] A. Levine,et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function , 2010, Proceedings of the National Academy of Sciences.
[15] J. Neuzil,et al. Mitochondrial complex II, a novel target for anti-cancer agents. , 2013, Biochimica et biophysica acta.
[16] T. Soga. Cancer metabolism: Key players in metabolic reprogramming , 2013, Cancer science.
[17] Saroj P. Mathupala,et al. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. , 2009, Seminars in cancer biology.
[18] H. Pelicano,et al. Glycolysis inhibition for anticancer treatment , 2006, Oncogene.
[19] W. Kaelin. New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. , 2010, Annals of the New York Academy of Sciences.
[20] Juliana Camacho-Pereira,et al. 3-Bromopyruvate inhibits calcium uptake by sarcoplasmic reticulum vesicles but not SERCA ATP hydrolysis activity. , 2012, The international journal of biochemistry & cell biology.
[21] J. Matés,et al. New insights into brain glutaminases: Beyond their role on glutamatergic transmission , 2009, Neurochemistry International.
[22] M. Shoshan. Potentiation of anti-cancer treatment by modulators of energy metabolism. , 2013, Current pharmaceutical biotechnology.
[23] Emma Saavedra,et al. Energy metabolism in tumor cells , 2007, The FEBS journal.
[24] D. Sabatini,et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.
[25] Gregory Stephanopoulos,et al. Quantifying Reductive Carboxylation Flux of Glutamine to Lipid in a Brown Adipocyte Cell Line* , 2008, Journal of Biological Chemistry.
[26] Jose Russo,et al. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. , 2012, Biochimica et biophysica acta.
[27] E. Chen. Mitochondrial dysfunction and cancer metastasis , 2012, Journal of Bioenergetics and Biomembranes.
[28] M. Brand,et al. Assessing mitochondrial dysfunction in cells , 2011, The Biochemical journal.
[29] Guido Kroemer,et al. Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.
[30] J. Hayashi,et al. Regulation of metastasis; mitochondrial DNA mutations have appeared on stage , 2012, Journal of Bioenergetics and Biomembranes.
[31] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[32] T. Reid,et al. The scarlet letter of alkylation: a mini review of selective alkylating agents. , 2012, Translational oncology.
[33] E. M. Smith,et al. Molecular cloning of a cDNA for rat hepatic glutaminase. Sequence similarity to kidney-type glutaminase. , 1990, The Journal of biological chemistry.
[34] P. Pedersen,et al. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. , 2001, Cancer letters.
[35] K. Vousden. Alternative fuel—another role for p53 in the regulation of metabolism , 2010, Proceedings of the National Academy of Sciences.
[36] Eva M. Schmelz,et al. Metabolic changes during ovarian cancer progression as targets for sphingosine treatment. , 2013, Experimental cell research.
[37] Martin G Pomper,et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.
[38] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[39] L. Neckers,et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis , 2013, Proceedings of the National Academy of Sciences.
[40] A. Galina,et al. Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase , 2012, Journal of Bioenergetics and Biomembranes.
[41] R. Curi,et al. Glutamine, gene expression, and cell function. , 2007, Frontiers in bioscience : a journal and virtual library.
[42] A. Goffeau. Drug resistance: The fight against fungi , 2008, Nature.
[43] G. Semenza. Regulation of metabolism by hypoxia-inducible factor 1. , 2011, Cold Spring Harbor symposia on quantitative biology.
[44] M. Tan,et al. Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.
[45] Christian M. Metallo,et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.
[46] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[47] V. Ganapathy,et al. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.
[48] F. Sotgia,et al. Mitochondrial metabolism in cancer metastasis , 2012, Cell cycle.